Media Summary: Andrew Yee, MD, Massachusetts General Hospital Cancer Center, Boston, MA, comments on the management of toxicities ... Watch the full course and our most up-to-date content here: Create a free account to track ... Adolfo Fernández-Sánchez, MD, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain, discusses a study investigating ...

Bcma - Detailed Analysis & Overview

Andrew Yee, MD, Massachusetts General Hospital Cancer Center, Boston, MA, comments on the management of toxicities ... Watch the full course and our most up-to-date content here: Create a free account to track ... Adolfo Fernández-Sánchez, MD, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain, discusses a study investigating ... Jaromir Tomasik, Medical University of Warsaw, Warsaw, Poland, provides insight into a meta-analysis of response rates to ... Andrew Yee, MD, Massachusetts General Hospital Cancer Center, Boston, MA, highlights the transformative impact of ... Felipe Prósper, MD, PhD, University of Navarra, Pamplona, Spain, discusses a study investigating the long-term cytopenia ...

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, comments on the emerging landscape of novel targets in multiple myeloma, ...

Photo Gallery

BCMA
Beyond CRS & ICANS: Insights Into Delayed Neurotoxicity After BCMA CAR-T Therapy in Myeloma | #EHA26
BCMA   Inter FIPS present Guys & Dolls Jr - highlights
Managing toxicities associated with BCMA-targeting bispecific antibodies in multiple myeloma
What is BCMA? #myeloma
The potential of soluble BCMA as an emerging biomarker in BCMA T-cell-redirecting therapies
BCMA | Sony a7SIII
Response rates to salvage therapies following anti-BCMA CAR-T failure in patients with myeloma
What is BCMA? #myeloma
What is BCMA Directed therapy? #myeloma
The transformative impact of BCMA-targeting bispecific antibodies in RRMM
Investigating the long-term cytopenia observed after BCMA-targeted CAR-T therapy in multiple myeloma
View Detailed Profile
BCMA

BCMA

Original video: http://www.youtube.com/watch?v=WK_eIik37X4&list=PLJMKS8LrXHN7bsTHIjBCQYkNiBiwblaBz&index=2.

Beyond CRS & ICANS: Insights Into Delayed Neurotoxicity After BCMA CAR-T Therapy in Myeloma | #EHA26

Beyond CRS & ICANS: Insights Into Delayed Neurotoxicity After BCMA CAR-T Therapy in Myeloma | #EHA26

BCMA

BCMA   Inter FIPS present Guys & Dolls Jr - highlights

BCMA Inter FIPS present Guys & Dolls Jr - highlights

BCMA

Managing toxicities associated with BCMA-targeting bispecific antibodies in multiple myeloma

Managing toxicities associated with BCMA-targeting bispecific antibodies in multiple myeloma

Andrew Yee, MD, Massachusetts General Hospital Cancer Center, Boston, MA, comments on the management of toxicities ...

What is BCMA? #myeloma

What is BCMA? #myeloma

Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity Create a free account to track ...

The potential of soluble BCMA as an emerging biomarker in BCMA T-cell-redirecting therapies

The potential of soluble BCMA as an emerging biomarker in BCMA T-cell-redirecting therapies

Adolfo Fernández-Sánchez, MD, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain, discusses a study investigating ...

BCMA | Sony a7SIII

BCMA | Sony a7SIII

BCMA

Response rates to salvage therapies following anti-BCMA CAR-T failure in patients with myeloma

Response rates to salvage therapies following anti-BCMA CAR-T failure in patients with myeloma

Jaromir Tomasik, Medical University of Warsaw, Warsaw, Poland, provides insight into a meta-analysis of response rates to ...

What is BCMA? #myeloma

What is BCMA? #myeloma

Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity Create a free account to track ...

What is BCMA Directed therapy? #myeloma

What is BCMA Directed therapy? #myeloma

Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity Create a free account to track ...

The transformative impact of BCMA-targeting bispecific antibodies in RRMM

The transformative impact of BCMA-targeting bispecific antibodies in RRMM

Andrew Yee, MD, Massachusetts General Hospital Cancer Center, Boston, MA, highlights the transformative impact of ...

Investigating the long-term cytopenia observed after BCMA-targeted CAR-T therapy in multiple myeloma

Investigating the long-term cytopenia observed after BCMA-targeted CAR-T therapy in multiple myeloma

Felipe Prósper, MD, PhD, University of Navarra, Pamplona, Spain, discusses a study investigating the long-term cytopenia ...

Promising targets in multiple myeloma: BCMA, GPRC5D, and FcRH5

Promising targets in multiple myeloma: BCMA, GPRC5D, and FcRH5

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, comments on the emerging landscape of novel targets in multiple myeloma, ...